Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells $10,596,375.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total value of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total value of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $478.58, for a total value of $10,768,050.00.

United Therapeutics Trading Down 0.8%

NASDAQ:UTHR opened at $478.93 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The firm has a market cap of $20.62 billion, a PE ratio of 18.15, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The stock has a fifty day moving average price of $486.76 and a 200 day moving average price of $425.24.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. UBS Group raised their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. HB Wealth Management LLC lifted its stake in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 35 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of United Therapeutics by 9.2% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,016 shares of the biotechnology company’s stock valued at $1,154,000 after acquiring an additional 338 shares during the period. Ascent Group LLC grew its position in shares of United Therapeutics by 21.7% during the second quarter. Ascent Group LLC now owns 874 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 156 shares during the last quarter. Finally, QRG Capital Management Inc. increased its holdings in shares of United Therapeutics by 6.2% in the 2nd quarter. QRG Capital Management Inc. now owns 17,770 shares of the biotechnology company’s stock valued at $5,106,000 after acquiring an additional 1,045 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.